Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
USP28 shRNA
- Development stage
- Preclinical
- Lead developer
- First Affiliated Hospital of Nanchang University
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
USP28 shRNA is a gene-silencing therapeutic candidate designed to target and reduce the expression of Ubiquitin Specific Peptidase 28 (USP28). USP28 is a deubiquitinating enzyme that plays a significant role in the progression of multiple myeloma (MM) by stabilizing KIF20B, which in turn activates the NF-κB signaling pathway. By utilizing short hairpin RNA (shRNA) to knockdown USP28, this approach induces cell cycle arrest at the G0/G1 phase and promotes apoptosis in MM cells. Preclinical research indicates that USP28 knockdown significantly reduces tumor burden in xenograft models and enhances the sensitivity of MM cells to the proteasome inhibitor bortezomib.
- Other names
- sh-USP28sh-USP-28sh-USP 28USP28 knockdownUSP-28 knockdownUSP 28 knockdown
02
Targets
USP28 (Ubiquitin-specific peptidase 28)
Beyond the preview
Go deeper on USP28 shRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on USP28 shRNA.